The immunoassay-based device, called the portable Bio-Detector integrated, can detect up to six organisms or toxins per assay chip in around 20 minutes.
The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.
The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.
The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
Bruker said it plans to use InVivo assets to explore antibody enrichment methods that could eliminate the need for culturing prior to MALDI-based microbial ID.
Bioyong will invest in test development as well as validation, regulatory approval, and commercialization in China and, possibly, other Asia-Pacific countries.
The company recently acquired intellectual property and personnel to drive development of PCR tests for applications including syndromic microbiology testing.
The report focused on identification of filamentous fungi and mycobacteria, and testing for resistance and susceptibility to antibiotics.